Q1 Earnings Estimate for MacroGenics Issued By HC Wainwright

MacroGenics, Inc. (NASDAQ:MGNX) – Equities research analysts at HC Wainwright upped their Q1 2025 earnings estimates for shares of MacroGenics in a research note issued on Tuesday, March 25th. HC Wainwright analyst R. Burns now expects that the biopharmaceutical company will earn ($0.69) per share for the quarter, up from their prior estimate of ($0.70). HC Wainwright has a “Neutral” rating and a $2.00 price target on the stock. The consensus estimate for MacroGenics’ current full-year earnings is ($1.06) per share. HC Wainwright also issued estimates for MacroGenics’ Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.89) EPS.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). MacroGenics had a negative net margin of 69.07% and a negative return on equity of 89.42%. The business had revenue of $49.40 million during the quarter, compared to analyst estimates of $34.17 million.

Separately, StockNews.com downgraded MacroGenics from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. Nine research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, MacroGenics has an average rating of “Hold” and a consensus price target of $7.38.

MacroGenics Stock Performance

Shares of NASDAQ:MGNX opened at $1.48 on Thursday. The business’s fifty day moving average price is $2.54 and its two-hundred day moving average price is $3.17. The stock has a market cap of $93.37 million, a PE ratio of -0.94 and a beta of 2.12. MacroGenics has a one year low of $1.46 and a one year high of $19.54.

Hedge Funds Weigh In On MacroGenics

Several institutional investors have recently added to or reduced their stakes in MGNX. Intech Investment Management LLC purchased a new stake in MacroGenics in the 3rd quarter valued at about $68,000. FMR LLC boosted its position in shares of MacroGenics by 1,230.1% in the third quarter. FMR LLC now owns 137,215 shares of the biopharmaceutical company’s stock worth $451,000 after acquiring an additional 126,899 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in MacroGenics by 374.4% in the third quarter. BNP Paribas Financial Markets now owns 90,779 shares of the biopharmaceutical company’s stock valued at $299,000 after purchasing an additional 71,643 shares during the period. Vestal Point Capital LP grew its holdings in MacroGenics by 3.8% in the third quarter. Vestal Point Capital LP now owns 830,000 shares of the biopharmaceutical company’s stock valued at $2,731,000 after purchasing an additional 30,000 shares during the period. Finally, Verition Fund Management LLC acquired a new position in MacroGenics during the third quarter worth approximately $297,000. 96.89% of the stock is currently owned by institutional investors and hedge funds.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.